BRNS vs EMN · $38.2M cap vs P/E 21, rev $9.38B
Barinthus Biotherapeutics plc (BRNS) versus Eastman Chemical Company (EMN) — a side-by-side from cached financials, not a winner call.
Barinthus Biotherapeutics plc (BRNS) is a biotechnology company listed on US.
Eastman Chemical Company (EMN) is a specialty chemicals company listed on US.
Latest reported BRNS revenue for 2025-09-30 was $0. Net income was -$14.6M. BRNS currently screens at market cap $38.2M.
Latest reported EMN revenue for 2024-12-31 was $9.38B. Net income was $908.0M. Revenue was up 1.9% from 2023-12-31 to 2024-12-31. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
BRNS currently screens at market cap $38.2M. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
Not investment advice. Open the BRNS and EMN stock pages for the full models.
Not investment advice.